线粒体移植治疗心血管疾病研究进展

心血管疾病的发病率和死亡率逐年升高,且在世界范围内的疾病负担中占据首位。线粒体功能异常可引起细胞到组织的病变,多种心血管疾病被证实与线粒体功能障碍有关。线粒体移植(mitochondria transplantation, MTP)是一种新兴的治疗手段,用于治疗因线粒体功能障碍引起的组织损伤。经过十多年从基础实验到临床试验的发展,MTP在心血管疾病中的治疗作用逐渐被证实,并且备受关注。该文就MTP的研究基础及其在心血管疾病中的研究进展进行综述。     

线粒体移植改善缺血再灌注损伤的作用及机制

当心脏手术、器官移植和血管病变时，血流停止以及之后血液再灌注过程都会对组织器官造成损伤，出现相应的功能障碍，即缺血再灌注损伤（ischemia-reperfusion injury,I/RI）。其中，线粒体功能障碍被认为是器官I/RI的重要原因之一，受损线粒体会导致细胞能量供应减少、活性氧（reactive oxygen species,ROS）生成增加、钙超载等结果，从而激活细胞死亡程序。线粒体是一种高度动态的细胞器，通过不断融合、分裂维持自身稳态，并且，线粒体已被研究证明可在细胞间转移。目前，线粒体提取技术较为成熟，可以从组织中提取出完整的、有活性的线粒体。在以上背景下，出现了线粒体移植（mitochondrial transplantation,MT）技术，通过移植活性线粒体至受损组织内，帮助细胞恢复功能。然而，MT的临床应用还面临着许多挑战，如MT的规范移植程序、作用机制和安全性等仍需要深入研究。本文就近10年MT改善I/RI的作用及相关机制进行了综述。     

线粒体移植疗法

线粒体移植(mitochondrial transplantation)曾指利用显微操作,将分离获得的正常线粒体注射到卵细胞的辅助生殖技术。近年兴起的,将线粒体直接注射到组织器官的受损部位,或注射到血液循环系统,进而发挥治疗作用的技术,同样被称为线粒体移植。在细胞研究水平,则是直接将线粒体与培养细胞共同孵育。这些技术方法也统称为线粒体疗法。该文系统综述了线粒体移植在心、脑、肝、肾、肺、骨骼肌等多种组织器官损伤模型中,在小鼠、大鼠、兔、猪等多种实验动物模型中的研究成果,以及在心脏病患儿体内的初步临床研究成果;介绍了学界提出的线粒体进入细胞、产生ATP等作用机制,及对此机制的相关质疑;同时介绍了自己课题组关于线粒体移植治疗皮肤急性光损伤和烧伤的研究成果,提出并讨论了线粒体可能不需要进入细胞即可发挥作用的假说。该文提出线粒体移植机制的内化机制和非内化机制概念,为深化线粒体移植机制研究指出新方向。     

线粒体移植治疗神经系统疾病的策略及机制

线粒体（mitochondria）承担细胞有氧呼吸功能，神经系统作为机体巨大耗能组织高度依赖线粒体结构和功能稳定。研究表明，线粒体异常是多种神经系统疾病发生发展的重要原因，靶向线粒体开发治疗神经系统疾病的策略已成为前沿和热点。其中，线粒体移植（mitochondrial transplantation）被认为有巨大治疗潜能。线粒体移植是将外源性健康线粒体以直接或间接方式移植进入受损机体，通过改善神经系统线粒体功能，最终达到改善或治疗神经系统疾病的目的。本篇综述回顾了线粒体移植治疗多种神经系统疾病的研究进展，重点阐述移植策略、细胞和分子机制及面对的挑战，以期为临床开发新的治疗手段提供线索与依据。     

线粒体自噬的研究进展

线粒体自噬（mitophagy）是指细胞通过自噬的机制选择性地清除线粒体的过程。选择性清除受损伤或功能不完整的线粒体对于整个线粒体网络的功能完整性和细胞生存来说十分关键。线粒体自噬的异常和很多疾病密切相关,因此对于线粒体自噬的具体分子机制以及生理意义研究有很重要的生物学意义。线粒体自噬的研究是目前生物学领域的研究热点,该文主要综述了近年来在线粒体自噬领域取得的研究进展,旨在为相关领域的研究提供参考。     

哺乳动物核移植中线粒体命运

线粒体是哺乳动物细胞中一种重要的产能、供能细胞器,与生长、发育、衰老和凋亡等多种细胞事件以及多种疾病有关.哺乳动物核移植中,供体细胞和受体卵胞质两种来源的线粒体在重构胚胎发育进程中的变化一直是科学家们研究的热点.对哺乳动物同种胚胎细胞核移植、同种体细胞核移植、异种核移植研究中线粒体的变化进行了综述.     

线粒体相关的疾病治疗及干预策略

线粒体疾病是一种累及不同的组织和器官的复杂异质性疾病,由核基因或线粒体基因的遗传缺陷导致,同时也受环境因素的影响。近十年来,有关线粒体疾病的诊断及发生机制的研究进展迅速,而疾病的治疗方法却研究较少。着重介绍线粒体疾病的相关治疗方法和干预策略。     

线粒体通透性转换孔在缺血预处理脑保护中的作用及机制

目的：线粒体通透性转换孔通透性改变是导致缺血再灌注损伤的原因,线粒体功能的致命性改变最终引起细胞凋亡,本研究旨在观察线粒体通透性转换孔（mitochondrial permeability transition pore,MPTP）在缺血再灌注及缺血预处理脑保护中的作用;方法：将体外培养8天的海马神经元细胞分为五组,正常对照组（A组）,缺血再灌注组（B组）,缺血预处理＋缺血再灌注组（C组）,苍术苷＋缺血再灌注组（D组）,缺血预处理＋苍术苷＋缺血再灌注组（E组）。使用流式细胞术检测各组细胞凋亡率,罗丹明123染色流式细胞术检测线粒体膜电位,Western-blot检测Bcl-2,Bax的表达。结果：与A组比较,其余四组线粒体膜电位均降低,神经元凋亡率升高（P〈0．05）;与B组比较,c组线粒体膜电位升高,神经元凋亡率升高,Bcl-2表达上调,Bax表达下调（P〈0．05）;与c组比较,E组粒体膜电位降低,神经元凋亡率升高,Bcl．2表达下调,Bax表达上调（P〈0．05）。结论：我们在细胞及分子生物学水平对MPTP及缺血预处理的研究后发现,缺血预处理能有效减轻海马神经元缺血再灌注损伤,抑制缺血再灌注后神经细胞凋亡,其机制与抑制MPTP的开放有关。     

线粒体移植增强人神经胶质瘤U87细胞的辐射敏感性

线粒体移植( mitochondrial transplantation)是从患者正常组织分离线粒体然后注入线粒体损伤或缺失的部位,使损伤细胞获得救治、器官功能得以恢复的全新干预技术。本研究重点探讨线粒体移植对人神经胶质瘤细胞(U87)辐射敏感性的影响。提取人星形胶质细胞(human astrocytes, HA)的线粒体,用荧光探针Mito-Tracker Red进行标记后再与U87细胞共培养,激光共聚焦显微镜观察发现,Mito-Tracker Red的红色荧光大量出现在U87细胞内;随后对进入细胞内的游离线粒体荧光强度进行定量分析,游离线粒体和U87细胞共培养12 h时,单细胞内荧光强度由本底值0.08上升至1.83,表明游离线粒体可以通过共培养方式进入U87细胞内。随后给予U87细胞X射线辐照,Western印迹结果显示,联合组与单独辐照组相比,Cyto-C和Bax的表达量分别由179.5%和198.5%升高至251.72%和256.10%,Bcl-2的表达量由57.17%降低至22.23%;使用Annexin V/PI双染法检测到联合组U87细胞凋亡量相比单独辐照组的3.1%和23.5%上升至19.2%和43.8%;RT-CES检测结果表明,96 h内联合组U87细胞生长曲线被抑制;联合组克隆形成率相对单独辐照组的53%下降至29.3%。鬼笔环肽染色发现,线粒体移植组细胞表面丝状伪足相比对照组明显减少。本研究提示,线粒体移植能够促进辐射诱导的肿瘤细胞凋亡,对U87细胞具有辐射增敏作用,其作用机制与重新激活线粒体凋亡通路、降低肿瘤恶性程度有关。     

线粒体在运动保护心肌免受缺血再灌注损伤中的作用

线粒体是参与心肌缺血再灌注(myocardial ischemia and reperfusion,MI/R)损伤的关键细胞器,线粒体活性氧(reactive oxygen species,ROS)爆发、Ca²⁺失调、线粒体通透性转换孔(mitochondrial permeability transition pore,mPTP)开放、线粒体肿胀、促凋亡蛋白释放等都会导致线粒体功能障碍,心肌功能受损。运动是预防MI/R损伤的有效干预手段,其保护作用可能通过线粒体来实现。运动保护MI/R损伤的线粒体机制由多种因素决定,如线粒体能量学、K_ATP通道、mPTP、线粒体跨膜电位(ΔΨ_m)、线粒体蛋白、线粒体脂质、线粒体质量控制、远程调控因子等。本文综述了MI/R产生的线粒体机制,运动对MI/R的保护作用以及线粒体在其中的作用,以期为MI/R损伤的线粒体治疗策略提供参考。     

The effects of mesenchymal stem cell mitochondrial transplantation on doxorubicin‐mediated nephrotoxicity in rats

The effect of dysfunctional mitochondria in several cell pathologies has been reported in renal diseases, including diabetic nephropathy and acute kidney injury. Previous studies have reported that mitochondrial transplantation provided surprising results in myocardial and liver ischemia, as well as in Parkinson's disease. We aimed to investigate the beneficial effects of isolated mitochondria transplantation from mesenchymal stem cells (MSCs) in vivo, to mitigate renal damage that arises from doxorubicin‐mediated nephrotoxicity and its action mechanism. In this study, a kidney model of doxorubicin‐mediated nephrotoxicity was used and isolated mitochondria from MSCs were transferred to the renal cortex of rats. The findings showed that the rate of isolated mitochondria from MSCs maintains sufficient membrane integrity, and was associated with a beneficial renal therapeutic effect. Following doxorubicin‐mediated renal injury, isolated mitochondria or vehicle infused into the renal cortex and rats were monitored for five days. This study found that mitochondrial transplantation decreased cellular oxidative stress and promoted regeneration of tubular cells after renal injury (P < .001, P = .009). Moreover, mitochondrial transplantation reduced protein accumulation of tubular cells and reversed renal deficits (P = .01, P < .001). Mitochondrial transplantation increased Bcl‐2 levels, and caspase‐3 levels decreased in injured renal cells (P < .015, P < .001). Our results provide a direct link between mitochondria dysfunction and doxorubicin‐mediated nephrotoxicity and suggest a therapeutic effect of transferring isolated mitochondria obtained from MSCs against renal injury. To our knowledge, this study is the first study in the literature that showed good therapeutic effects of mitochondrial transplantation in a nephrotoxicity model, which is under‐researched.     

Development of Mitochondrial Gene Replacement Therapy

Many "classic" mitochondrial diseases have been described that arise from single homoplasmic mutations in mitochondrial DNA (mtDNA). These diseases typically affect nonmitotic tissues (brain, retina, muscle), present with variable phenotypes, can appear sporadically, and are untreatable. Evolving evidence implicates mtDNA abnormalities in diseases such as Alzheimer's, Parkinson's, and type II diabetes, but specific causal mutations for these conditions remain to be defined. Understanding the mtDNA genotype-phenotype relationships and developing specific treatment for mtDNA-based diseases is hampered by inability to manipulate the mitochondrial genome. We present a novel protein transduction technology ("protofection") that allows insertion and expression of the human mitochondrial genome into mitochondria of living cells. With protofection, the mitochondrial genotype can be altered, or exogenous genes can be introduced to be expressed and either retained in mitochondria or be directed to other organelles. Protofection also delivers mtDNA in vivo, opening the way to rational development of mitochondrial gene replacement therapy of mtDNA-based diseases.     

Mitochondrial pharmaceutics

Since the end of the 1980s, key discoveries have been made which have significantly revived the scientific interest in a cell organelle, which has been studied continuously and with steady success for the last 100 years. It has become increasingly evident that mitochondrial dysfunction contributes to a variety of human disorders, ranging from neurodegenerative and neuromuscular diseases, obesity, and diabetes to ischemia-reperfusion injury and cancer. Moreover, since the middle of the 1990s, mitochondria, the 'power house' of the cell, have also become accepted as the cell's 'arsenals' reflecting their increasingly acknowledged key role during apoptosis. Based on these recent developments in mitochondrial research, increased pharmacological and pharmaceutical efforts have lead to the emergence of 'Mitochondrial Medicine' as a whole new field of biomedical research. Targeting of biologically active molecules to mitochondria in living cells will open up avenues for manipulating mitochondrial functions, which may result in the selective protection, repair or eradication of cells. This review gives a brief synopsis over current strategies of mitochondrial targeting and their possible therapeutic applications.     

Mitochondrial quality control in stroke: From the mechanisms to therapeutic potentials

Mitochondrial damage is a critical contributor to stroke‐induced injury, and mitochondrial quality control (MQC) is the cornerstone of restoring mitochondrial homeostasis and plays an indispensable role in alleviating pathological process of stroke. Mitochondria quality control promotes neuronal survival via various adaptive responses for preserving mitochondria structure, morphology, quantity and function. The processes of mitochondrial fission and fusion allow for damaged mitochondria to be segregated and facilitate the equilibration of mitochondrial components such as DNA, proteins and metabolites. The process of mitophagy is responsible for the degradation and recycling of damaged mitochondria. This review aims to offer a synopsis of the molecular mechanisms involved in MQC for recapitulating our current understanding of the complex role that MQC plays in the progression of stroke. Speculating on the prospect that targeted manipulation of MQC mechanisms may be exploited for the rationale design of novel therapeutic interventions in the ischaemic stroke and haemorrhagic stroke. In the review, we highlight the potential of MQC as therapeutic targets for stroke treatment and provide valuable insights for clinical strategies.     

心衰进程中非编码RNA对线粒体功能的调控作用

心衰长久以来一直缺少有效治疗方法,给社会造成了巨大的经济和民生负担,新诊断标志物的确认和治疗方法的研发十分迫切。线粒体功能障碍与心衰发生和发展密切相关,以线粒体为基础的能量供应紊乱、钙失衡、氧化应激和细胞死亡在心衰的发展中起着重要作用,但线粒体调控的具体机制还不十分清楚。非编码RNA被证实在表观调控、转录后修饰、翻译调节等多方面发挥重要调控作用。研究表明,包括miRNA、lncRNA、circRNA在内的大量非编码RNA在心脏发育和心脏疾病发展过程中存在差异表达,并在线粒体蛋白稳态、氧化磷酸化、氧化应激、凋亡与自噬等调控中发挥了重要作用,进而影响心衰等心脏疾病的发生发展,但其详细机制尚未完全阐明。本文就近年心衰发生和发展过程中非编码RNA调控线粒体功能机制的相关研究进行综述,梳理了近年来非编码RNA在调节线粒体结构与功能进而影响心衰发展方面的研究进展,以期为心衰研究与治疗提供新的思路和靶点。     

AMPK对线粒体功能的调节

5’单磷酸腺苷活化蛋白激酶（AMP—activated protein kinase,AMPK）是细胞的能量感受器,调节细胞能量代谢,在正常细胞和癌细胞中均发挥重要的生物功能,它的激活有助于纠正代谢紊乱,使细胞代谢趋向生理平衡。在细胞应急反应中,细胞感受到能量危机,ATP浓度下降,AMP浓度上升,细胞内AMP／ATP比例上升,AMPK被激活：而在病理状态下,如代谢综合征、肿瘤等,常伴随能量代谢紊乱和AMPK激活抑制,因此,AMPK被视为治疗代谢性疾病与肿瘤的潜在作用靶点。然而,AMPK对能量代谢的调节与线粒体的功能密不可分,线粒体作为细胞的能量工厂,在健康与疾病中也发挥着重要的作用。越来越多的研究表明,线粒体能影响AMPK的活性,同时AMPK也通过多方面对线粒体进行调节,线粒体相关疾病与AMPK的调节有着密切的关系。该文主要针对AMPK是如何对线粒体的合成、线粒体自噬、内源性凋亡及线粒体相关疾病等方面进行综述。     

线粒体质量控制与米色脂肪之间的关系

近年来,肥胖患病率不断上升,肥胖已成为全球性公共卫生问题.肥胖能够增加高血压、冠心病等心血管疾病的发病风险,防治肥胖已经成为亟待解决的社会问题.米色脂肪是一种产热型脂肪细胞,可在受到寒冷、药物、运动等外界刺激下由白色脂肪细胞转化而来,但其形态和功能却与白色脂肪细胞不同,而与棕色脂肪细胞类似,即米色脂肪同样含有丰富的线粒...     

线粒体DNA异质性

线粒体 DNA（mitochondrial DNA,mtDNA）是线粒体内最重要的遗传物质。mtDNA 突变普 遍存在,突变型 mtDNA 与野生型 mtDNA 共存的现象被称为 mtDNA 异质性。mtDNA 异质性与衰老和多种疾病密切相关。mtDNA异质性特性、mtDNA 异质性与衰老和疾病相关性以及线粒体疾病的治疗等都是近年来遗传学研究的热点。本文从 mtDNA 异质性的动态变化、组织特异性、mtDNA 异质性与疾病以及线粒体疾病的治疗等方面对 mtDNA 异质性进行综述。